Up­dat­ed: Mod­er­na: Not enough flu cas­es in PhI­II tri­al yet to tell ef­fi­ca­cy

One of Mod­er­na’s Phase III stud­ies for its in­fluen­za vac­cine can­di­date for adults, dubbed mR­NA-1010, did not have enough cas­es at the time of the in­ter­im ef­fi­ca­cy analy­sis to de­clare ear­ly suc­cess, the com­pa­ny an­nounced Tues­day.

A rep­re­sen­ta­tive for Mod­er­na told End­points News there were not enough peo­ple in­fect­ed dur­ing the time of the study.

The NIH’s Da­ta and Safe­ty Mon­i­tor­ing Board rec­om­mend­ed con­tin­u­ing to test the shot for ef­fi­ca­cy in the North­ern Hemi­sphere tri­al, which is sup­posed to pro­tect against four dif­fer­ent in­fluen­za strains.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER